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coronary angiographic (QCA) analysis as ‘CAD’ (patients with ≥1 coronary stenosis
of ≥70% severity or ≥50% if left main stem) and ‘No CAD’ (Group 2).
Results: 54 patients (32.9%) had significant CAD prior to TAVI, with 10 (6.5%)
undergoing PCI prior to their procedure. The CAD group had more males (70.4% v
51.0%, p=0.02) and a greater proportion with previous PCI (27.8% v 11.5%, p=0.01).
[|#7#|][|#7#|]At a mean follow up of 337±275 days (mean±SD), the overall mortality
in the CAD group was higher (35.2% v 16.3%, p=0.007), as were 30-day (16.7% v
3.8%, p=0.005) and 12 month mortalities (31.5% v 14.4%, p=0.01). Kaplan Meier
analysis confirmed the increase in mortality with the presence of CAD (logrank=0.02).
The incidence of MACCE was not significantly different (35.2% v 23.1%, p=0.11).
[|#7#|][|#7#|]Amongst the 10 patients who underwent PCI in Group 1, 8 had single
vessel intervention and 2 had PCI to 2 vessels. Mortality in this sub-group was not
significantly different from the CAD patients who did not receive PCI (50% versus
31.8%, p=0.28).
Conclusion: The presence of significant CAD as defined by QCA analysis increased
overall, 30-day and 12 month mortality in patients after TAVI in our study. As yet, the
impact of PCI to significant CAD upon outcome after TAVI is not clear and will be
assessed in a prospective, randomised controlled trial.
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Background: The need for permanent pacemaker is a recognized complication of
Transcatheter aortic valve implantation (TAVI) with the CoreValve prosthesis. The
purpose of the present analysis was to evaluate the need of permanent pacemaker after
TAVI with the CoreValve prosthesis using the new Accutrak delivery system.
Methods: Between April 2008 and May 2011, a total of 195 consecutive patients with
symptomatic aortic valve stenosis underwent TAVI using the self expanding CoreValve
revalving prosthesis. In 124 patients the traditional delivery system (TS) and the
remaining were performed using the Accutrak delivery system.
Results: The mean age and logistic EuroSCORE was similar in both groups (TS vs.
Accutrak): 79.4 ± 6.7 vs. 78.3 ± 6.5 and 20.6 ± 13% vs. 18.6 ± 10%, respectively. The
procedural success rates were 97.5% for TS and 100% for Accutrak. There were no
significant differences in baseline ECG characteristics between patients who use the
traditional system compared with Accutrak: PR interval 153 ± 46 mm vs. 165 ± 30
mm, p = 0.127; LBBB 22 (20.2%) vs. 8 (12.7%), p = 0.213; RBBB 21 (19.3%) vs. 8
(12.7%) p = 0.268; anterior and posterior hemiblock, 28 (25.9%) vs. 12 (19.1%) p =
0.342. The depth of the prosthesis in the left ventricular outflow tract (LVOT) was
greater with TS compared with Accutrak (9.6 ± 3.2 mm vs. 6.4 ± 3 mm, p < 0.001),
and the need for permanent requirement pacemaker was higher with TS than Accutrak
(35.1% vs. 14.3%, p = 0.003).
Conclusion: The new Accutrak delivery System allows a better position of the
CoreValve prosthesis with less depth in the LVOT and this could be related to the lower
rate of permanent pacemaker
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Background: The safety and efficacy of a true percutaneous approach in transfemoral-
transcatheter aortic valve implantation (TAVI) have not been described in a large
prospective cohort. The purpose of this study was to evaluate the incidence of vascular
complications and the predictors of Prostar failure for this approach.
Methods: Among 337 patients included in our prospective TAVI database (October
2006 to April 2011), transfemoral-TAVI was performed in 208 patients. True
percutaneous approach was performed in 176 consecutive patients since March 2008.
Successful closure with Prostar was defined as adequate hemostasis without Prostar-
related vascular complications. We compared the clinical outcomes in our early and
late experience according to the VARC definitions. The first 88 cases defined the “early
experience group”.
Results: Patients were 83.0±7.2 years old and EuroSCORE 24.0±11.6%. The Edwards
valve was used in 136 cases (18-24Fr) and the CoreValve in 40 (18Fr). The sheath
outer diameter/minimal femoral diameter ratio (SFAR) was 0.96±0.14. Successful
closure was achieved in 91.2%, and was significantly increased (96.3% vs 86.8%,
p=0.045) in the late experience group. Cross-over to surgery was required in 2.2%.
Vascular complications occurred in 19.9%, and were significantly lower in the late
experience group (11.0% vs 26.5%, p=0.017). Major vascular complications (2.9% vs
14.0%, p=0.018) were decreased in the late experience group. Early experience
(HR:19.16, 95%CI:3.04-136.89, p<0.001), increased BMI (HR:1.34, 95%CI:1.04-1.72,
p=0.033) and SFAR (HR:98.07, 95%CI:1.12-8746.20, p=0.045) predicted Prostar
failure by multivariate analysis.
Conclusion: True percutaneous transfemoral-TAVI is feasible and associated with a
high rate of success and a low rate of complications after a learning phase. Other
predictors of failure are higher BMI and SFAR. Further application of this technique
provides less invasive approach to these high-risk patients.
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Background: Multiple medical reimbursement systems exist in Europe, which may
create unequal dissemination and coverage of innovative medical devices. Even in the
setting of regularly revised systems, uptake of new technology may be delayed leading
to unequal reimbursement.
Methods: This study analyzed the 2010 trends of transcatheter aortic valve
implantation (TAVI) rates in 14 countries (Medtronic CoreValve System and Edwards
Sapien). Implant data were gathered from BIBA Medical, a UK-based provider of
market analysis for the medical device industry. Demographic and economic data were
gathered from Eurostat, a statistical office of the European Union. Regression
techniques were used to explore the relationship between implant rate and a number
of key variables.
Results: In 2010, a total of 14,400 TAVI procedures were documented providing an
average country-based implant rate of 36.2 per million/Inhabitants. A seven-fold
difference in implantation rate existed between the highest and lowest implanting
countries (Germany, 77 per mil/inhab. vs. Norway 12 per mil/inhab.). Implant rates
were correlated with per-capita gross domestic product (GDP) (r2=0,015), health
expenditure (r2=0.15)and number of implanting centers in the country (r2=0.18). At
this time, only two European countries have a dedicated tariff for TAVI that is
applicable nationwide and covers both the device and the procedure (Germany €34,900,
France €28,477). Differences between country-specific tariffs depend on the method
of DRG calculation. In Austria, the TAVI tariff was made to equal that of surgical aortic
valve replacement. Countries such the UK and Italy have adopted case-by-case
funding. In countries such as Belgium and the Netherlands TAVI is funded by the
hospital-based budget.
Conclusion: Significant differences in TAVI rates exist among Europe; per-capita GDP,
health expenditure, implanting centers, and regional differences in reimbursement
policies may help explain these differences. These observations may help us to better
understand unequal patterns of dissemination and coverage of innovative medical
devices such as TAVI.
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Background: Transcatheter aortic valve implantation (TAVI) is a rapidly evolving
technique for high-risk patients with significant aortic stenosis. Suitable aortic annulus
sizes (AAS) for the 2 currently available devices range from 18-27 mm for the Edwards
SAPIEN Valve and 20-27 mm for the Medtronic CoreValve Prosthesis. Contrast-
enhanced multi-slice computed tomography (MSCT) has been established in recent
years for reproducible measurement of AAS. Aim of study was to obtain gender-related
values of AAS derived by MSCT in elderly, high-risk patients scheduled for TAVI and
to verify, if the currently available, CE marked TAVI devices are sufficient for the
treatment of the vast majority of this collective.
Methods: We retrospectively analyzed 1004 symptomatic patients (81.03+/-6.48 years,
range 48.51 to 98.53 years; 468 men (46.6%)) with severe AVS scheduled for TAVI
between 04/2005 and 10/2010. In all patients, a contrast-enhanced ECG-gated MSCT
(64-slice dual source CT scanner) was performed pre-interventionally as part of the
routine TAVI screening process. Measurement of AAS was performed by 3D-
multiplanar reconstruction. For the currently available TAVI devices, patients AAS
was classified in 3 subgroups: 1=AAS too small (< 18.0 mm); 2=AAS adequate (18.0
to 27.0 mm); 3=AAS oversized (> 27.0 mm).
Results: AAS in the overall population was 24.7+/-2.5 mm (mean+/-SD). AAS in men
was 26.1+/-2.3mm and in women 23.5+/-1.9mm. Comparing gender-related values
women showed a significantly smaller AAS (p=0.001). In 83.6% of patients, AAS was
within the required range (group 2). In 0.2% AAS was “too small” (group 1) whereas
in 16.2% of patients (group 3) AAS was “oversized” for the currently available devices.
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